http://www.drugdiscoverytoday.com/ Copyright Elsevier Ltd Intuitiv Ltd (www.intuitiv.net) Sat, 04 Feb 2012 09:54:19 GMT http://www.drugdiscoverytoday.com/ http://www.drugdiscoverytoday.com/_common/img/template/ddt/site-logo.gif http://www.drugdiscoverytoday.com/view/23402/drug-discovery-today-january-issue/ The latest issue of Drug Discovery Today is packed full of industry focused research articles, new developments in drug discovery, and expert comment and opinion. Mon, 23 Jan 2012 15:10:00 GMT http://www.drugdiscoverytoday.com/view/23402/drug-discovery-today-january-issue/ http://www.drugdiscoverytoday.com/view/23619/psychiatric-drugs-as-effective-as-other-drugs/ Psychiatric drugs are as effective as drugs used to treat many physical health problems, according to a major review published in the February issue of the British Journal of Psychiatry. Wed, 01 Feb 2012 18:00:00 GMT http://www.drugdiscoverytoday.com/view/23619/psychiatric-drugs-as-effective-as-other-drugs/ http://www.drugdiscoverytoday.com/view/23543/ogt-founder-professor-sir-ed-southern-awarded-the-2011-mrc-millennium-medal/ Professor Sir Ed Southern, founder of Oxford Gene Technology (OGT), a provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has been awarded the 2011 Medical Research Council (MRC) Millennium Medal. Mon, 30 Jan 2012 14:00:00 GMT http://www.drugdiscoverytoday.com/view/23543/ogt-founder-professor-sir-ed-southern-awarded-the-2011-mrc-millennium-medal/ http://www.drugdiscoverytoday.com/view/23404/scientists-reveal-first-3d-image-of-cancerprevention-molecule-/ Cancer Research UK scientists have created the first 3D structure of a key protein that protects against the development of cancer, according to research published in Nature Structural & Molecular Biology. Mon, 23 Jan 2012 16:40:00 GMT http://www.drugdiscoverytoday.com/view/23404/scientists-reveal-first-3d-image-of-cancerprevention-molecule-/ http://www.drugdiscoverytoday.com/view/23400/rapid-rise-in-opioid-abuse-is-among-the-challenges-faced-by-pain-therapy-drug-developers/ Pain therapy drug developers address the rapid rise in prescription drug abuse alongside the need for safe and effective treatments for a growing number of chronic pain sufferers. The sector has a diverse pipeline, with reformulations of existing therapies and alternative modes of drug delivery in development alongside novel compounds. However, increased generic competition will temper market growth over the next decade. Mon, 23 Jan 2012 13:58:00 GMT http://www.drugdiscoverytoday.com/view/23400/rapid-rise-in-opioid-abuse-is-among-the-challenges-faced-by-pain-therapy-drug-developers/ http://www.drugdiscoverytoday.com/view/23392/together-we-will-beat-cancer/ Despite the doom and gloom surrounding the pharmaceutical industry and the many commentaries highlighting inefficiencies of the sectors operating model, 2011 has proven to be a near-record year for approvals of innovative new drugs. These approvals include seven new cancer treatments with two of these (Pfizer’s crizotinib, Xalkori™ and Roche’s vemurafenib, Zelboraf™) made in conjunction with companion genetic tests, reinforcing the notion that the practice of stratified medicine has truly arrived. The forthcoming special issue of Drug Discovery Today on cancer highlights innovative contributions in basic, translational and clinical research made by UK scientists and clinicians in the fight against cancer. Mon, 23 Jan 2012 11:12:00 GMT http://www.drugdiscoverytoday.com/view/23392/together-we-will-beat-cancer/ http://www.drugdiscoverytoday.com/view/23267/charity-bids-to-rid-africa-of-blinding-disease/ Development charity Sightsavers has today unveiled a 10-year campaign to help eliminate one of the world’s leading causes of preventable blindness, termed onchocerciasis (also river blindness). With plans to fundraise and invest more than £27 million over the next decade to help combat this neglected tropical disease (NTD) across Africa, the charity is starting work this month in the Democratic Republic of the Congo where the disease is endemic. Tue, 17 Jan 2012 11:45:00 GMT http://www.drugdiscoverytoday.com/view/23267/charity-bids-to-rid-africa-of-blinding-disease/ http://www.drugdiscoverytoday.com/view/23157/new-cluster-for-life-sciences-as-biocity-scotland-secures-a-future-for-msd-newhouse-site/ BioCity Scotland Ltd, a joint venture between BioCity Nottingham and Roslin BioCentre, has today announced the acquisition of the former-MSD research facility at Newhouse, Lanarkshire. This exciting deal will enable the development of a dedicated base in central Scotland for growing bioscience, pharmaceutical, med tech and healthcare companies. Wed, 11 Jan 2012 17:30:00 GMT http://www.drugdiscoverytoday.com/view/23157/new-cluster-for-life-sciences-as-biocity-scotland-secures-a-future-for-msd-newhouse-site/ http://www.drugdiscoverytoday.com/view/22984/reprogrammed-oestrogen-binding-linked-to-more-aggressive-breast-cancer/ Scientists based at Cancer Research UK’s Cambridge Research Institute have discovered how receptors for the female sex hormone oestrogen attach to a different part of the DNA in breast cancer patients who are more likely to relapse, according to a study published in Nature. Thu, 05 Jan 2012 11:00:00 GMT http://www.drugdiscoverytoday.com/view/22984/reprogrammed-oestrogen-binding-linked-to-more-aggressive-breast-cancer/ http://www.drugdiscoverytoday.com/view/22682/uk-biobank-launch-of-procedures-for-accessing-the-resource/ UK Biobank launches its Access Procedures today (Wednesday 14th), which govern the way the resource can be used by scientists to improve the health of future generations. Wed, 14 Dec 2011 16:32:00 GMT http://www.drugdiscoverytoday.com/view/22682/uk-biobank-launch-of-procedures-for-accessing-the-resource/ http://www.drugdiscoverytoday.com/view/22675/government-uk-life-sciences-strategy-a-significant-step-forward/ The BioIndustry Association (BIA) welcomes the Prime Minister's announcement of a coordinated life sciences strategy which could provide a foundation for the future of the bioscience sector in the UK Wed, 14 Dec 2011 14:21:00 GMT http://www.drugdiscoverytoday.com/view/22675/government-uk-life-sciences-strategy-a-significant-step-forward/ http://www.drugdiscoverytoday.com/view/22579/the-long-term-cost-of-inferior-database-quality/ This month’s editorial is written by Antony J. Williams and Sean Ekins. “If I have seen further than others, it is by standing upon the shoulders of giants.”Isaac Newton Fri, 09 Dec 2011 16:39:00 GMT http://www.drugdiscoverytoday.com/view/22579/the-long-term-cost-of-inferior-database-quality/ http://www.drugdiscoverytoday.com/view/22470/treatment-with-januvia-sitagliptin-associated-with-fewer-major-cardiovascular-events-in-people-with-type-2-diabetes-compared-with-a-sulphonylurea/ A new pooled analysis presented today at the International Diabetes Federation (IDF) 21st World Diabetes Congress has demonstrated that people with type 2 diabetes taking 'Januvia' (sitagliptin) experienced a lower incidence of major cardiovascular (CV) events (MACE) compared to those treated with a sulphonylurea (SU). Tue, 06 Dec 2011 15:35:00 GMT http://www.drugdiscoverytoday.com/view/22470/treatment-with-januvia-sitagliptin-associated-with-fewer-major-cardiovascular-events-in-people-with-type-2-diabetes-compared-with-a-sulphonylurea/ http://www.drugdiscoverytoday.com/view/22439/drug-discovery-oxford-2012/ The Drug Discovery Oxford 2012 – “Drug discovery: a job too complex for academia or industry alone?” conference is only a month away. Mon, 05 Dec 2011 17:38:00 GMT http://www.drugdiscoverytoday.com/view/22439/drug-discovery-oxford-2012/ http://www.drugdiscoverytoday.com/view/22374/horizon-2020-a-new-research-framework-for-developing-and-sharing-knowledge/ The European Federation of Pharmaceutical Industries and Associations (EFPIA), the voice of the research-based pharmaceutical industry in Europe, welcomes the launch of the European Commission’s new Framework for Research and Innovation: Horizon 2020. Thu, 01 Dec 2011 10:42:00 GMT http://www.drugdiscoverytoday.com/view/22374/horizon-2020-a-new-research-framework-for-developing-and-sharing-knowledge/ http://www.drugdiscoverytoday.com/view/22297/cambridgeelan-centre-for-research-innovation-and-drug-discovery-launched/ The University of Cambridge and Elan Corporation plc today announced the launch of The Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre), which will be located at the University of Cambridge, England. Mon, 28 Nov 2011 12:23:00 GMT http://www.drugdiscoverytoday.com/view/22297/cambridgeelan-centre-for-research-innovation-and-drug-discovery-launched/ http://www.drugdiscoverytoday.com/view/22227/celgene-marks-uk-expansion-with-opening-of-new-headquarters/ Celgene, one of the world’s largest developers of biopharmaceuticals has demonstrated its commitment to UK expansion with the opening of its new London headquarters, accommodating its growing numbers of UK staff and the Celgene global regulatory and drug safety teams. Wed, 23 Nov 2011 17:26:00 GMT http://www.drugdiscoverytoday.com/view/22227/celgene-marks-uk-expansion-with-opening-of-new-headquarters/ http://www.drugdiscoverytoday.com/view/22222/critical-considerations-for-your-biomarker-strategy/ Biomarkers. There was a time in the not-so-distant past when simply identifying a biomarker was considered a drug discovery success. Like the low hanging fruit initially exposed by the genomic revolution, that once common view has long since disappeared. Today, the line between the bench and the clinic is becoming increasingly blurred. Translational science has become a core element of the drug discovery paradigm, and with it has come an increasing need for an integrated, multidisciplinary approach to biomarker development. Wed, 23 Nov 2011 13:49:00 GMT http://www.drugdiscoverytoday.com/view/22222/critical-considerations-for-your-biomarker-strategy/ http://www.drugdiscoverytoday.com/view/22079/new-approach-to-benefitrisk-offers-informed-tailored-decisionmaking-for-nonprescription-medicines/ As consumers and health systems move toward greater reliance on self-care, regulatory and clinical decision making should be improved through new tools to assess the unique benefits and challenges of self-care nonprescription [‘over-the-counter’, (OTC)] products, according to a new White Paper published in the peer-reviewed journal Clinical Pharmacology & Therapeutics. Wed, 16 Nov 2011 17:21:00 GMT http://www.drugdiscoverytoday.com/view/22079/new-approach-to-benefitrisk-offers-informed-tailored-decisionmaking-for-nonprescription-medicines/ http://www.drugdiscoverytoday.com/view/22022/pantarhei-bioscience-announces-discovery-of-antigen-zp3-as-a-treatment-to-combat-ovarian-cancer/ Pantarhei Bioscience, a specialty pharmaceutical company focusing on the development of innovative, proprietary treatments in the fields of women’s health and endocrine cancer, announces the publication in the Journal of the Federation of American Societies for Experimental Biology (FASEB J October 5, 2011) of the results of an innovative treatment strategy for ovarian cancer, which has now been selected to appear in the Faculty of 1000 (F1000) emphasizing its significance. Tue, 15 Nov 2011 10:45:00 GMT http://www.drugdiscoverytoday.com/view/22022/pantarhei-bioscience-announces-discovery-of-antigen-zp3-as-a-treatment-to-combat-ovarian-cancer/ http://www.drugdiscoverytoday.com/view/22004/proceedings-of-the-2nd-annual-london-genetics-pharmacogenetics-conference-2010-pharmacogenetics-why-how-and-when/ The importance of pharmacogenetics and stratified medicine as part of the drug development processes is now widely acknowledge, offering the opportunity to address many of the challenges facing the biopharmaceutical industry today and supporting an era where cost-effectiveness and value-based pricing rule. Moving on from the inaugural London Genetics Pharmacogenetic conference in 2009, at which the role of pharmacogenetics in drug discovery and development was debated, the 2nd London Genetics conference, entitled ‘Pharmacogenetics – Why, How and When?’ focused on how and when to apply stratified approaches from drug discovery through to cost-effectiveness evaluation and reimbursement. Mon, 14 Nov 2011 15:00:00 GMT http://www.drugdiscoverytoday.com/view/22004/proceedings-of-the-2nd-annual-london-genetics-pharmacogenetics-conference-2010-pharmacogenetics-why-how-and-when/ http://www.drugdiscoverytoday.com/view/21991/worlds-first-stem-cell-bandage-in-human-clinical-trials/ The company behind a pioneering stem cell bandage, believed to be the world’s first adult and autologous (patient’s own) stem cell treatment designed to heal torn meniscal cartilage, can now take the technology to human clinical trials thanks to an investment from one of the UK’s most successful entrepreneurs. Mon, 14 Nov 2011 12:19:00 GMT http://www.drugdiscoverytoday.com/view/21991/worlds-first-stem-cell-bandage-in-human-clinical-trials/ http://www.drugdiscoverytoday.com/view/21889/are-you-running-on-empty-new-educational-campaign-launched-to-raise-awareness-of-hypoglycaemia-among-drivers-with-type-2-diabetes-and-their-healthcare-professionals/ A new educational campaign is being launched in the UK to educate people with type 2 diabetes on ‘hypoglycaemia’ and how it can be prevented and managed. The ‘Are You Running on Empty?’ campaign is collaboration between Diabetes Nursing Group, TREND, The Automobile Association (AA) and MSD Diabetes. Tue, 08 Nov 2011 12:36:00 GMT http://www.drugdiscoverytoday.com/view/21889/are-you-running-on-empty-new-educational-campaign-launched-to-raise-awareness-of-hypoglycaemia-among-drivers-with-type-2-diabetes-and-their-healthcare-professionals/ http://www.drugdiscoverytoday.com/view/21880/almac-publishes-stage-ii-colon-cancer-recurrence-signature-in-the-journal-of-clinical-oncology/ Almac’s Diagnostics business unit today announced the publication of its stage II colon cancer recurrence signature (diagnostic test) in the Journal of Clinical Oncology. Tue, 08 Nov 2011 10:48:00 GMT http://www.drugdiscoverytoday.com/view/21880/almac-publishes-stage-ii-colon-cancer-recurrence-signature-in-the-journal-of-clinical-oncology/ http://www.drugdiscoverytoday.com/view/21724/domainex-awarded-technology-strategy-board-funding-to-support-its-research-into-a-novel-cancer-drug/ Domainex Ltd, the UK-based drug discovery company focused on speed and innovation, has been awarded a £250,000 grant by the Technology Strategy Board (TSB), the UK’s national innovation agency, to help support the development of a new drug for the treatment of several common cancers. Tue, 01 Nov 2011 10:38:00 GMT http://www.drugdiscoverytoday.com/view/21724/domainex-awarded-technology-strategy-board-funding-to-support-its-research-into-a-novel-cancer-drug/ http://www.drugdiscoverytoday.com/view/21515/21st-century-database-of-traditional-chinese-medicine-released/ A comprehensive database developed by King’s College London researchers that features the chemical components found in traditional Chinese medicines has been released to market this month, enabling researchers to explore age-old remedies in the search for tomorrow’s new drugs. Fri, 21 Oct 2011 12:00:00 GMT http://www.drugdiscoverytoday.com/view/21515/21st-century-database-of-traditional-chinese-medicine-released/ http://www.drugdiscoverytoday.com/view/21461/findings-from-diagenic-pfizer-rd-collaboration-show-promising-early-results-for-bloodbased-test-for-early-alzheimer-disease/ DiaGenic reports preliminary positive findings from the collaborative R&D project with Pfizer Inc. where the objective is to identify blood-based biomarkers that may be useful in diagnosing and monitoring Alzheimer’s disease. Wed, 19 Oct 2011 14:26:00 GMT http://www.drugdiscoverytoday.com/view/21461/findings-from-diagenic-pfizer-rd-collaboration-show-promising-early-results-for-bloodbased-test-for-early-alzheimer-disease/ http://www.drugdiscoverytoday.com/view/21432/diabetes-and-its-complications-a-disease-of-epidemic-proportions/ Diabetes is the theme of this month’s edition of Drug Discovery Today’s Editor’s Choice newsletter. According to the latest data published by the World Health Organization (WHO) approximately 346 million people worldwide are living with diabetes today. If left untreated, chronic hyperglycemia can lead to several macrovascular and microvascular diabetic complications. In spite of the epidemic proportions, exploding healthcare costs, and the great impact this disease has on patients, health care providers, health care systems and insurers, to date, no cures have been identified yet. Tue, 18 Oct 2011 14:00:00 GMT http://www.drugdiscoverytoday.com/view/21432/diabetes-and-its-complications-a-disease-of-epidemic-proportions/ http://www.drugdiscoverytoday.com/view/21316/study-shows-that-roches-investigational-drug-for-alzheimers-disease-removes-amyloid-plaques-from-the-brain/ Roche announced the publication of a study demonstrating that its monoclonal antibody gantenerumab removes amyloid plaques from the brain of patients with Alzheimer’s disease. Wed, 12 Oct 2011 15:53:00 GMT http://www.drugdiscoverytoday.com/view/21316/study-shows-that-roches-investigational-drug-for-alzheimers-disease-removes-amyloid-plaques-from-the-brain/ http://www.drugdiscoverytoday.com/view/21284/genetic-discovery-opens-possibility-of-a-universal-worldwide-diagnostic-test/ Six new genetic variants will help identify diagnostic markers and drug targets for the 55 million Asian’s affected. Tue, 11 Oct 2011 14:14:00 GMT http://www.drugdiscoverytoday.com/view/21284/genetic-discovery-opens-possibility-of-a-universal-worldwide-diagnostic-test/ http://www.drugdiscoverytoday.com/view/21254/new-research-shows-chronic-pain-is-not-being-adequately-measured/ New research released today to mark European Week Against Pain reveals that, in more than half of cases, peoples’ levels of pain across Europe are not being adequately assessed. Mon, 10 Oct 2011 15:23:00 GMT http://www.drugdiscoverytoday.com/view/21254/new-research-shows-chronic-pain-is-not-being-adequately-measured/ http://www.drugdiscoverytoday.com/view/21176/a-hormone-that-fights-fat-with-fat/ Sanford-Burnham scientists reveal that a hormone called orexin prevents obesity in mice by activating brown fat, a tissue that’s good at burning calories. Thu, 06 Oct 2011 10:28:00 GMT http://www.drugdiscoverytoday.com/view/21176/a-hormone-that-fights-fat-with-fat/ http://www.drugdiscoverytoday.com/view/21094/proteomic-study-published-in-nature-paves-the-way-for-new-treatment-for-incurable-leukaemia-using-an-epigenetic-inhibitor/ A study published in Nature online today (Dawson et al. Advanced online Publication, DOI: 10.1038/nature10509) by Cellzome and others has identified that a small molecule inhibitor of BET proteins could potentially be used to treat the aggressive and often incurable mixed lineage (MLL-fusion) leukaemia. Mon, 03 Oct 2011 15:27:00 GMT http://www.drugdiscoverytoday.com/view/21094/proteomic-study-published-in-nature-paves-the-way-for-new-treatment-for-incurable-leukaemia-using-an-epigenetic-inhibitor/ http://www.drugdiscoverytoday.com/view/21080/cancer-research-technology-and-cancer-research-uk-establish-lipid-metabolism-research-team-/ Cancer Research Technology (CRT), Cancer Research UK’s commercial arm, has established a group of scientists with expertise in lipid metabolism – getting energy from fats and making building blocks for cell growth – to develop targets for potential new cancer drugs. Mon, 03 Oct 2011 10:57:00 GMT http://www.drugdiscoverytoday.com/view/21080/cancer-research-technology-and-cancer-research-uk-establish-lipid-metabolism-research-team-/ http://www.drugdiscoverytoday.com/view/21058/jeanpierre-garnier-elected-as-chairman-of-actelions-board-of-directors-/ Actelion Ltd announced that Jean-Pierre Garnier has become Chairman of the Board of Directors of the Swiss biopharmaceutical company. The Board of Directors elected him at their meeting today, 27 September 2011. To ensure a smooth transition, Robert Cawthorn, who has been Chairman since the inception of the company, will stay on the Board as planned until the 2012 Annual General Meeting. Fri, 30 Sep 2011 10:33:00 GMT http://www.drugdiscoverytoday.com/view/21058/jeanpierre-garnier-elected-as-chairman-of-actelions-board-of-directors-/ http://www.drugdiscoverytoday.com/view/21005/silence-therapeutics-signs-sirna-delivery-collaboration-with-top-10-pharma-company/ Silence Therapeutics, a leading RNA interference therapeutics company, announces that it has entered into an agreement with one of the world's leading global pharmaceutical companies to investigate the application of Silence's proprietary DACC delivery technology for intravenous delivery of short interfering RNA sequences to the pulmonary vascular endothelium. Wed, 28 Sep 2011 10:59:00 GMT http://www.drugdiscoverytoday.com/view/21005/silence-therapeutics-signs-sirna-delivery-collaboration-with-top-10-pharma-company/ http://www.drugdiscoverytoday.com/view/20989/the-path-towards-personalised-medicine/ Pharmacogenetics is the theme of this month’s edition of Drug Discovery Today Editor’s Choice. This coincides with the Drug Discovery Today special issue, ‘Pharmacogenetics and Stratified Medicine’. Tue, 27 Sep 2011 17:11:00 GMT http://www.drugdiscoverytoday.com/view/20989/the-path-towards-personalised-medicine/ http://www.drugdiscoverytoday.com/view/20981/catching-up-on-circulating-tumor-cell-technology/ Circulating tumor cells (CTCs) are cells that ‘escape’ from primary tumor cells and migrate into the bloodstream, where they circulate through the body. CTCs were first identified in the 1980s as cells that had the morphology of tumor cells but were found in the blood. Over the past two decades technological innovations have eased the detection and analysis of CTCs. The resulting investigations of CTCs are an important area of clinical research because they are demonstrating that CTCs have potential clinical value as warning signals of cancer progression. Tue, 27 Sep 2011 15:31:00 GMT http://www.drugdiscoverytoday.com/view/20981/catching-up-on-circulating-tumor-cell-technology/ http://www.drugdiscoverytoday.com/view/20940/global-pharmaceutical-industry-contributes-action-plan-and-research-to-fighting-noncommunicable-diseases-in-the-developing-world/ To coincide with the United Nations High-Level Meeting on non-communicable diseases (NCDs), the research-based pharmaceutical industry has outlined the steps it is taking to address the rise of NCDs in the developing world. Mon, 26 Sep 2011 12:11:00 GMT http://www.drugdiscoverytoday.com/view/20940/global-pharmaceutical-industry-contributes-action-plan-and-research-to-fighting-noncommunicable-diseases-in-the-developing-world/ http://www.drugdiscoverytoday.com/view/20853/prosensa-advances-three-exon-skipping-candidates-for-duchenne-muscular-dystrophy-into-the-next-development-stage/ Prosensa, the Dutch biopharmaceutical company focusing on rare diseases with an unmet medical need, announced today that they have agreed with GlaxoSmithKline (GSK) to advance three further exon skipping compounds (PRO044, PRO045 and PRO053) into the next development stage under their ongoing collaboration relationship in Duchenne Muscular Dystrophy (DMD). Tue, 20 Sep 2011 15:50:00 GMT http://www.drugdiscoverytoday.com/view/20853/prosensa-advances-three-exon-skipping-candidates-for-duchenne-muscular-dystrophy-into-the-next-development-stage/ http://www.drugdiscoverytoday.com/view/20819/oxford-scanner-reveals-secrets-of-documents-ancient-and-modern/ A scanner which combines the convenience of a desktop scanner with the functionality of a powerful laboratory imaging device has been developed at the University of Oxford’s Classics Department, and is now being commercialised by a new company Oxford Multi Spectral Limited which was today spun out by the University’s technology transfer company Isis Innovation. Mon, 19 Sep 2011 11:19:00 GMT http://www.drugdiscoverytoday.com/view/20819/oxford-scanner-reveals-secrets-of-documents-ancient-and-modern/ http://www.drugdiscoverytoday.com/view/20440/university-research-team-to-develop-new-treatment-for-rare-childhood-disease/ A team of researchers at Robert Gordon University has secured a six figure sum from Sparks, a leading children’s medical research charity, to develop a revolutionary treatment for a rare genetic disorder. Wed, 31 Aug 2011 14:27:00 GMT http://www.drugdiscoverytoday.com/view/20440/university-research-team-to-develop-new-treatment-for-rare-childhood-disease/ http://www.drugdiscoverytoday.com/view/20326/trophos-awarded-key-us-patent-covering-use-of-novel-cardioprotective-compound-tro40303/ Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of their novel mitochondrial pore modulator, TRO40303, for cytoprotection. The patent provides coverage for the use of Trophos’ TRO40303 to reduce the cardiac reperfusion injury that contributes significantly to the morbidity and mortality seen after a heart attack [myocardial infarction (MI)]. Fri, 26 Aug 2011 12:26:00 GMT http://www.drugdiscoverytoday.com/view/20326/trophos-awarded-key-us-patent-covering-use-of-novel-cardioprotective-compound-tro40303/ http://www.drugdiscoverytoday.com/view/20359/nanotherapeutics-opportunities-and-challenges/ This month’s Drug Discovery Today Editor’s Choice brings you unique perspectives on the potential of nanomedicines and the associated regulatory landscape, from researchers across the globe. We highlight four nanotechnology-related reviews from Drug Discovery Today and related publications that discuss the emerging concepts in the development of targeted therapeutic and imaging nanodevices, their path to clinical translation, and how they are being viewed from a regulatory environment. Fri, 26 Aug 2011 10:50:00 GMT http://www.drugdiscoverytoday.com/view/20359/nanotherapeutics-opportunities-and-challenges/ http://www.drugdiscoverytoday.com/view/20331/mission-therapeutics-a-new-cambridgebased-spinout-company-secures-6m-in-seriesa-funding-led-by-sofinnova-partners/ A team led by Professor Stephen Jackson together with Cancer Research Technology (Cancer Research UK’s commercial arm) and the University of Cambridge has announced the launch of MISSION Therapeutics Ltd, with Series A funding from a top venture capital syndicate. Thu, 25 Aug 2011 12:56:00 GMT http://www.drugdiscoverytoday.com/view/20331/mission-therapeutics-a-new-cambridgebased-spinout-company-secures-6m-in-seriesa-funding-led-by-sofinnova-partners/ http://www.drugdiscoverytoday.com/view/20285/kalvista-pharmaceuticals-launched-with-8-million-in-series-a-funding-to-develop-novel-class-of-drugs-for-diabetic-macular-edema/ KalVista Pharmaceuticals, a new ophthalmology company with a focus on diabetic macular edema (DME), has raised £8 million in a series A round from leading life sciences investors Novo A/S and SV Life Sciences. Wed, 24 Aug 2011 09:53:00 GMT http://www.drugdiscoverytoday.com/view/20285/kalvista-pharmaceuticals-launched-with-8-million-in-series-a-funding-to-develop-novel-class-of-drugs-for-diabetic-macular-edema/ http://www.drugdiscoverytoday.com/view/20119/scientists-discover-how-cancers-generate-musclelike-contractions-to-spread-around-the-body/ Cancer Research UK-funded scientists have discovered that a protein called JAK triggers contractions in tumours which enable cancer cells to squeeze though tiny spaces and spread. Tue, 16 Aug 2011 10:26:00 GMT http://www.drugdiscoverytoday.com/view/20119/scientists-discover-how-cancers-generate-musclelike-contractions-to-spread-around-the-body/ http://www.drugdiscoverytoday.com/view/20090/how-fatty-diets-cause-diabetes/ High levels of fat shut down a key enzyme that promotes glucose sensing in pancreatic beta cells, revealing a pathway implicated in the Type 2 diabetes epidemic. Mon, 15 Aug 2011 10:24:00 GMT http://www.drugdiscoverytoday.com/view/20090/how-fatty-diets-cause-diabetes/ http://www.drugdiscoverytoday.com/view/19918/pradaxa-gains-approval-for-stroke-prevention-in-atrial-fibrillation-in-europe/ The European Commission (EC) approved Boehringer Ingelheim’s breakthrough oral anticoagulant, Pradaxa® (dabigatran etexilate) for the prevention of stroke in patients with atrial fibrillation (AF) at risk of stroke. This EU label extension means that, for the first time in over 50 years, millions of AF patients across Europe will have access to a new treatment for the prevention of AF-related strokes, which is effective and convenient, and has demonstrated a good safety profile. Fri, 05 Aug 2011 16:00:00 GMT http://www.drugdiscoverytoday.com/view/19918/pradaxa-gains-approval-for-stroke-prevention-in-atrial-fibrillation-in-europe/ http://www.drugdiscoverytoday.com/view/19649/new-cancer-treatment-device-goes-into-service-/ A treatment system called the Novalis® Tx™ has gone into service, which has the ability to destroy cancerous cells virtually anywhere in the body in a single, 20-minute session, without the need for a single cut of the scalpel. Mon, 25 Jul 2011 16:35:00 GMT http://www.drugdiscoverytoday.com/view/19649/new-cancer-treatment-device-goes-into-service-/ http://www.drugdiscoverytoday.com/view/19635/pharmaceutical-rd-in-the-next-decade-a-perpetually-moving-storm/ The pharmaceutical industry is facing tremendous challenges moving forward into the new millennium. These range from expiring patents on blockbuster drugs, to thin pipelines and stiffer regulatory hurdles, to name but a few; if it sounds like a major crisis then it probably is. In general, crisis management, which involves dealing with threats after they have occurred, is the result of poor risk management or inadequate strategic planning. As a result, the industry has seen an increase in mergers and acquisitions (M&A) activity, which has resulted in job losses, mandatory efficiency campaigns across all R&D disciplines and an explosion in tapping emerging markets through outsourcing and acquisition-based market penetration. Mon, 25 Jul 2011 10:35:00 GMT http://www.drugdiscoverytoday.com/view/19635/pharmaceutical-rd-in-the-next-decade-a-perpetually-moving-storm/ http://www.drugdiscoverytoday.com/view/19557/celebrating-success-2011-announced-as-the-international-year-of-chemistry/ The United Nations Educational, Scientific and Cultural Organization (UNESCO) and International Union of Pure and Applied Chemistry (IUPAC) announced in 2008 that The International Year of Chemistry (IYC) would be celebrated in 2011. This exciting initiative celebrates success in chemistry hopefully to spark renewed excitement for the future of discovery in chemistry. IYC 2011 is an opportunity to encourage young, enthusiastic scientists, to celebrate the contribution of advancements in chemistry within our society and promote appreciation for women in science. By Ellen Smyth Wed, 20 Jul 2011 16:29:00 GMT http://www.drugdiscoverytoday.com/view/19557/celebrating-success-2011-announced-as-the-international-year-of-chemistry/ http://www.drugdiscoverytoday.com/view/19521/convergence-pharmaceuticals-announces-start-of-phase-ii-study-for-cnv1014802/ Convergence Pharmaceuticals today announced that the Phase II proof of concept study with CNV1014802 for treating pain associated with lumbosacral radiculopathy (LSR) has started. Tue, 19 Jul 2011 15:48:00 GMT http://www.drugdiscoverytoday.com/view/19521/convergence-pharmaceuticals-announces-start-of-phase-ii-study-for-cnv1014802/ http://www.drugdiscoverytoday.com/view/19369/gilead-licence-expands-access-but-several-countries-left-out/ An agreement announced today by pharmaceutical company Gilead to licence several HIV/AIDS drugs to the Medicines Patent Pool could improve access to medicines for patients. However, this agreement excludes several countries with large numbers of people living with HIV, the international medical humanitarian organisation Médecins Sans Frontières (MSF) said today. Tue, 12 Jul 2011 17:34:00 GMT http://www.drugdiscoverytoday.com/view/19369/gilead-licence-expands-access-but-several-countries-left-out/ http://www.drugdiscoverytoday.com/view/19203/detox-protein-is-collaborator-in-pancreatic-and-lung-cancer-development/ Cancer Research UK scientists have revealed that a ‘detox’ protein which mops up harmful ‘reactive oxygen’ in cells could also trigger pancreatic and lung cancer development, according to a study published in Nature. Wed, 06 Jul 2011 19:00:00 GMT http://www.drugdiscoverytoday.com/view/19203/detox-protein-is-collaborator-in-pancreatic-and-lung-cancer-development/ http://www.drugdiscoverytoday.com/view/19175/government-to-invest-in-new-research-to-tackle-threat-caused-by-sepsis/ The Technology Strategy Board and the Department of Health are to invest up to £7.5 million in new research and development that aims to improve the future diagnosis, detection and management of sepsis, a life-threatening illness caused by the body overreacting to an infection. Tue, 05 Jul 2011 14:41:00 GMT http://www.drugdiscoverytoday.com/view/19175/government-to-invest-in-new-research-to-tackle-threat-caused-by-sepsis/ http://www.drugdiscoverytoday.com/view/18988/therapeutic-peptides-a-revival-of-interest-/ The innovation process in the pharmaceutical industry is, as for all evolutionary models of technological change, both ‘pushed by technology’ and ‘demand driven’. The core of the innovation relies on the research for new high value-added drugs to address unmet medical needs. To this end, tens of billions of dollars are invested per year in R&D. However, the decreasing number of approved drugs, which is accompanied by increasing R&D expenditures, demands alternative approaches to increase R&D productivity. This situation contributes to a revival of interest in peptides as potential tools and drug candidates. Tue, 28 Jun 2011 13:57:00 GMT http://www.drugdiscoverytoday.com/view/18988/therapeutic-peptides-a-revival-of-interest-/ http://www.drugdiscoverytoday.com/view/18749/horizon-successfully-completes-pilot-human-geneediting-program-with-leading-pharma/ Horizon Discovery (Horizon), a leading provider of research tools to support the development of personalized medicines, has announced that it has successfully completed an eighteen month pilot program with Novartis, designed to test the ability of Horizon’s GENESISTM rAAV gene-editing platform to generate human isogenic cell lines for use by Novartis pre-clinical research programs. Thu, 16 Jun 2011 18:26:00 GMT http://www.drugdiscoverytoday.com/view/18749/horizon-successfully-completes-pilot-human-geneediting-program-with-leading-pharma/ http://www.drugdiscoverytoday.com/view/18623/target-of-15-million-people-on-hiv-treatment-by-2015-secured-at-aids-summit/ A global United Nations Summit on AIDS has taken a critical step by committing to reach 15 million people with HIV treatment by 2015. Mon, 13 Jun 2011 14:00:00 GMT http://www.drugdiscoverytoday.com/view/18623/target-of-15-million-people-on-hiv-treatment-by-2015-secured-at-aids-summit/ http://www.drugdiscoverytoday.com/view/18572/research-and-development-into-tumour-profiling-will-lead-to-improved-cancer-care/ Six new collaborative research and development projects are set to receive nearly £6 million of government funding in the latest stage of a major five-year initiative to ensure that the UK is a world leader in the development of personalised medicine. Fri, 10 Jun 2011 10:32:00 GMT http://www.drugdiscoverytoday.com/view/18572/research-and-development-into-tumour-profiling-will-lead-to-improved-cancer-care/ http://www.drugdiscoverytoday.com/view/18550/encouraging-data-on-the-immune-response-to-the-new-men-b-vaccine-in-tots-and-teens/ Meningitis Research Foundation (MRF) welcomes new data released today by Novartis Vaccines and Diagnostics, revealing a robust immune response in babies, toddlers and teenagers to their new Men B vaccine candidate (4CMenB), currently submitted for licence to the EMA. Thu, 09 Jun 2011 14:16:00 GMT http://www.drugdiscoverytoday.com/view/18550/encouraging-data-on-the-immune-response-to-the-new-men-b-vaccine-in-tots-and-teens/ http://www.drugdiscoverytoday.com/view/18476/first-female-scientist-appointed-deputy-government-chemist/ LGC, the international market leader in analytical, forensic and diagnostic services and reference standards, announces the appointment of Selvarani Elahi as Deputy Government Chemist. Tue, 07 Jun 2011 17:00:00 GMT http://www.drugdiscoverytoday.com/view/18476/first-female-scientist-appointed-deputy-government-chemist/ http://www.drugdiscoverytoday.com/view/18407/new-treatment-hope-for-diabetes-and-cardiovascular-diseases-/ A cutting-edge research project at the University of Leicester is aiming to improve the treatment of diabetes and cardiovascular diseases. Fri, 03 Jun 2011 16:58:00 GMT http://www.drugdiscoverytoday.com/view/18407/new-treatment-hope-for-diabetes-and-cardiovascular-diseases-/ http://www.drugdiscoverytoday.com/view/18288/the-view-from-here-admetox/ This month’s Drug Discovery Today Editor’s Choice newsletter is concerned with the field of ADME-Tox. We are highlighting aspects of this rapidly-expanding discipline with some recently published reviews from the pages of Drug Discovery Today. Tue, 31 May 2011 12:00:00 GMT http://www.drugdiscoverytoday.com/view/18288/the-view-from-here-admetox/ http://www.drugdiscoverytoday.com/view/18187/breaking-news-for-the-elrig-drug-discovery-2011-meeting-in-manchester-uk-september-78/ ELRIG are pleased to announce that Dr Jamie Thomson, Wisconsin University, one of the world’s leading experts in stem cell biology, has been confirmed as one of the Keynote Speakers for this conference. Tue, 31 May 2011 00:00:00 GMT http://www.drugdiscoverytoday.com/view/18187/breaking-news-for-the-elrig-drug-discovery-2011-meeting-in-manchester-uk-september-78/ http://www.drugdiscoverytoday.com/view/18232/edinburgh-startup-creates-worlds-first-fluorescent-protein-3d-hologram-to-further-biomedical-research/ A University of Edinburgh based start-up company has created the world’s first 3D hologram based on the properties of a Nobel Prize winning scientific discovery, which enhances biomedical research into the behavioural activity of proteins. Thu, 26 May 2011 15:32:00 GMT http://www.drugdiscoverytoday.com/view/18232/edinburgh-startup-creates-worlds-first-fluorescent-protein-3d-hologram-to-further-biomedical-research/ http://www.drugdiscoverytoday.com/view/18185/elrig-bioprocess-conference/ The ELRIG meeting on High Throughput BioProcess development is only a few weeks away. Wed, 25 May 2011 11:42:00 GMT http://www.drugdiscoverytoday.com/view/18185/elrig-bioprocess-conference/ http://www.drugdiscoverytoday.com/view/18043/discovery-of-gene-ripple-effect-which-causes-cervical-cancer-to-advance-and-spread/ Cancer Research UK scientists have discovered that a common gene fault in cervical cancer cells triggers a ripple of molecular signals, which makes the disease more aggressive, according to research published in The Journal of Pathology. Wed, 18 May 2011 16:43:00 GMT http://www.drugdiscoverytoday.com/view/18043/discovery-of-gene-ripple-effect-which-causes-cervical-cancer-to-advance-and-spread/ http://www.drugdiscoverytoday.com/view/18011/leeds-scientists-to-lead-groundbreaking-investigation-into-treatment-of-cervical-cancer/ A pioneering investigation into the treatment of cervical cancer will take place at the University of Leeds following a major advancement in the study of the disease. Tue, 17 May 2011 12:00:00 GMT http://www.drugdiscoverytoday.com/view/18011/leeds-scientists-to-lead-groundbreaking-investigation-into-treatment-of-cervical-cancer/ http://www.drugdiscoverytoday.com/view/17990/first-in-class-pain-killer-palexia-sr-launched-in-the-uk-for-the-treatment-of-severe-chronic-pain/ Today sees the launch of Palexia® SR (tapentadol prolonged release) for the oral treatment of adults with severe chronic pain, which can only be adequately managed with opioid analgesics. Palexia® SR is the first in a new class of centrally acting analgesics called MOR-NRI, which has two mechanisms of action in one molecule; both µ-opioid receptor (MOR) agonism and noradrenaline reuptake inhibition (NRI). Mon, 16 May 2011 13:47:00 GMT http://www.drugdiscoverytoday.com/view/17990/first-in-class-pain-killer-palexia-sr-launched-in-the-uk-for-the-treatment-of-severe-chronic-pain/ http://www.drugdiscoverytoday.com/view/17893/new-marker-offers-hope-for-more-reliable-detection-of-prostate-cancer/ A new, promising marker for diagnosing prostate cancer has been discovered by Uppsala researchers with the aid of a unique method developed at the Department of Immunology, Genetics and Pathology. The study, being published this week in the journal Proceedings of the National Academy of Sciences, PNAS, can lead to more reliable diagnoses and fewer unnecessary operations. Wed, 11 May 2011 10:00:00 GMT http://www.drugdiscoverytoday.com/view/17893/new-marker-offers-hope-for-more-reliable-detection-of-prostate-cancer/ http://www.drugdiscoverytoday.com/view/17819/sir-michael-rawlins-to-be-new-president-of-the-royal-society-of-medicine/ Professor Sir Michael Rawlins, the current Chairman of NICE (the National Institute for Health and Clinical Excellence) has been elected as the next President of the Royal Society of Medicine. Fri, 06 May 2011 14:13:00 GMT http://www.drugdiscoverytoday.com/view/17819/sir-michael-rawlins-to-be-new-president-of-the-royal-society-of-medicine/ http://www.drugdiscoverytoday.com/view/17794/asthma-pill-more-userfriendly-than-inhalers-and-no-less-effective/ A rarely prescribed asthma drug is easier to use and just as effective as conventional treatment with inhalers, according to a new study led by the University of East Anglia (UEA). Thu, 05 May 2011 15:29:00 GMT http://www.drugdiscoverytoday.com/view/17794/asthma-pill-more-userfriendly-than-inhalers-and-no-less-effective/ http://www.drugdiscoverytoday.com/view/17792/drug-delivery-enabling-technology-for-drug-discovery-and-development/ Although drug delivery may not attract the attention and press coverage of some of the other disciplines involved in drug discovery, it is equally important in the development of a successful product. Effective drug delivery can be the difference between getting a molecule into clinical trial rather than a chemical sitting in a brown bottle on the shelf, or a forgotten compound languishing in a 96 well storage plate. It can mean the difference between a drug that just wipes its feet in the market and the discovery of a blockbuster. Thu, 05 May 2011 15:19:00 GMT http://www.drugdiscoverytoday.com/view/17792/drug-delivery-enabling-technology-for-drug-discovery-and-development/ http://www.drugdiscoverytoday.com/view/17652/lithium-treatment-could-slow-progression-of-memory-loss/ Lithium treatment helps slow the progression of memory loss, according to new research, published in the British Journal of Psychiatry. The finding raises the possibility that lithium could one day be used to prevent Alzheimer’s disease. Thu, 28 Apr 2011 12:00:00 GMT http://www.drugdiscoverytoday.com/view/17652/lithium-treatment-could-slow-progression-of-memory-loss/ http://www.drugdiscoverytoday.com/view/17598/4antibody-ag-meets-first-milestone-in-boehringer-ingelheim-collaboration/ 4-Antibody AG has announced that the Company has achieved the successful completion of a first milestone in its ongoing collaboration with Boehringer Ingelheim. Wed, 27 Apr 2011 08:54:00 GMT http://www.drugdiscoverytoday.com/view/17598/4antibody-ag-meets-first-milestone-in-boehringer-ingelheim-collaboration/ http://www.drugdiscoverytoday.com/view/17576/breath-test-could-identify-headandneck-cancer-patients/ Scientists reveal that an ‘electronic nose’ can distinguish between molecules found in the breath of head-and-neck cancer patients and those of healthy people, according to the results of a small, initial study, published in the British Journal of Cancer. Tue, 26 Apr 2011 08:52:00 GMT http://www.drugdiscoverytoday.com/view/17576/breath-test-could-identify-headandneck-cancer-patients/ http://www.drugdiscoverytoday.com/view/17556/a-common-genetic-basis-between-epilepsy-and-autism-has-been-identified/ Neurophysiologists of the Istituto Italiano di Tecnologia (Iit) and the University of Genoa, together with geneticists of the Centre Hospitalier de l’Université de Montréal have demonstrated the involvement of the Synapsin-1 gene (SYN1) in epilepsy and autism. Thu, 21 Apr 2011 15:26:00 GMT http://www.drugdiscoverytoday.com/view/17556/a-common-genetic-basis-between-epilepsy-and-autism-has-been-identified/ http://www.drugdiscoverytoday.com/view/17478/horizon-discovery-and-fox-chase-cancer-center-announce-collaboration-to-apply-raav-gene-targeting-in-mouse-embryonic-stem-cells-and-research-into-egfrtherapy-resistance/ Horizon Discovery (Horizon), a leading provider of research tools to support the development of personalized medicines, has announced that it has entered into a 3-year collaboration with the Fox Chase Cancer Center (Fox Chase). The focus of the collaboration is to apply rAAV gene targeting in mouse embryonic stem (ES) cells, and for the discovery of genes involved in resistance to EGFR-targeted therapies in human cancer, such as PI3K. Tue, 19 Apr 2011 15:25:00 GMT http://www.drugdiscoverytoday.com/view/17478/horizon-discovery-and-fox-chase-cancer-center-announce-collaboration-to-apply-raav-gene-targeting-in-mouse-embryonic-stem-cells-and-research-into-egfrtherapy-resistance/ http://www.drugdiscoverytoday.com/view/17280/babraham-scientists-reveal-how-white-blood-cells-get-activated-in-autoimmune-disease-helping-to-target-better-drugs-for-these-disorders-/ Scientists at the Babraham Institute have discovered a critical piece of the jigsaw that explains how a type of immune cell – a white blood cell known as a neutrophil – is activated by antibodies. The research, published today in the journal Science Signaling, brings new understanding to how the Phosphatidylinositol 3-kinase (PI3K) signalling pathway is used to regulate neutrophil function. This may pave the way for the development of a strategy to specifically inhibit the inappropriate activation of these immune cells that is seen in auto-immune inflammatory conditions such as rheumatoid arthritis, glomerulonephritis and some skin blistering diseases. Tue, 12 Apr 2011 11:31:00 GMT http://www.drugdiscoverytoday.com/view/17280/babraham-scientists-reveal-how-white-blood-cells-get-activated-in-autoimmune-disease-helping-to-target-better-drugs-for-these-disorders-/ http://www.drugdiscoverytoday.com/view/17175/cellular-feast-or-famine/ Study shows how cells decide whether they have enough fat – a molecular checkpoint that, when disturbed, could lead to obesity or other diseases. Thu, 07 Apr 2011 12:42:00 GMT http://www.drugdiscoverytoday.com/view/17175/cellular-feast-or-famine/ http://www.drugdiscoverytoday.com/view/17008/why-stem-cells-dont-just-want-to-make-neurons/ Research being presented today (01 April) at the UK National Stem Cell Network annual science conference provides another piece in the puzzle of why it can be so hard to produce large numbers of the same type of cell in the lab - a process that is vital for scaling up stem cell production for therapeutic use. This knowledge will help researchers to develop strategies for obtaining the desired cell type for use in either research or medicine. Fri, 01 Apr 2011 12:32:00 GMT http://www.drugdiscoverytoday.com/view/17008/why-stem-cells-dont-just-want-to-make-neurons/ http://www.drugdiscoverytoday.com/view/16974/targeting-epigenetics-not-just-drugs-for-cancer/ Epigenetics is effectively the study of changes in gene function by covalent modifications. Such modifications result in a stably heritable phenotype that does not involve a change in DNA sequence. There are effectively 2 routes by which such covalent changes can be effected; first by methylation of C5 cytosine bases located 5’ to guanosines. This route is referred to as the cytosine methylation code. In addition, the histone component of chromosomes can be covalently modified at the N-terminus, the so-called histone code. Thu, 31 Mar 2011 13:00:00 GMT http://www.drugdiscoverytoday.com/view/16974/targeting-epigenetics-not-just-drugs-for-cancer/ http://www.drugdiscoverytoday.com/view/16812/senectus-therapeutics-and-astrazeneca-collaborate-to-identify-triggers-to-cell-aging/ Senectus Therapeutics has signed a deal to screen a selection of AstraZeneca’s chemical compound library to identify those which trigger a key element of cancer cell ageing – called senescence. Senescent cells are those which after many rounds of cell growth and division enter a ‘sleep’ phase where the normal cell cycle is stopped. This blocks the uncontrolled growth and division of cells. It is a natural mechanism to prevent cancer. But cancer cells find ways to trick their way past this block and continue to grow and divide. Understanding the triggers to cell ageing may reveal molecular targets for completely new ways to treat cancer. Wed, 23 Mar 2011 14:13:00 GMT http://www.drugdiscoverytoday.com/view/16812/senectus-therapeutics-and-astrazeneca-collaborate-to-identify-triggers-to-cell-aging/ http://www.drugdiscoverytoday.com/view/16708/lack-of-alignment-threatens-drug-discovery-process/ With looming patient cliffs, drying pipelines and the need for open collaboration, now more than ever the pharma sector needs a co-ordinated approach to get back on track, says a leading industry player. Fri, 18 Mar 2011 09:25:00 GMT http://www.drugdiscoverytoday.com/view/16708/lack-of-alignment-threatens-drug-discovery-process/ http://www.drugdiscoverytoday.com/view/16558/elsevier-announces-the-anxiety-and-depression-21st-neuropharmacology-conference/ Elsevier, the leading publisher of scientific, technical and medicalinformation products and services, today announced that the Anxiety andDepression: 21st Neuropharmacology Annual Conference will take place in Virginia, USA on 10-11 November 2011 as a satellite to the 2011 Meeting of the Society for Neuroscience. Fri, 11 Mar 2011 09:30:00 GMT http://www.drugdiscoverytoday.com/view/16558/elsevier-announces-the-anxiety-and-depression-21st-neuropharmacology-conference/ http://www.drugdiscoverytoday.com/view/16410/scientist-gets-his-mind-around-alzheimers/ It’s not known what causes the disease or how to cure it. And the stakes have never been higher. But one European neuroscientist is leading the charge to uncover new treatments for this neurodegenerative disease. Mon, 07 Mar 2011 13:38:00 GMT http://www.drugdiscoverytoday.com/view/16410/scientist-gets-his-mind-around-alzheimers/ http://www.drugdiscoverytoday.com/view/16339/clear-english-coming-to-your-medicine-cabinet/ Confusing instructions on medicine bottles and packets of pills dispensed from UK pharmacies are to be replaced with simpler words and phrases from this month. Thu, 03 Mar 2011 11:55:00 GMT http://www.drugdiscoverytoday.com/view/16339/clear-english-coming-to-your-medicine-cabinet/ http://www.drugdiscoverytoday.com/view/16329/metabolomics-study-provides-insight-into-gliomaassociated-metabolic-changes/ Metabolon, Inc., announces the publication of “Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome”, in The Proceedings of the National Academy of Sciences (PNAS 108 (8) 3270-3275). Thu, 03 Mar 2011 08:56:00 GMT http://www.drugdiscoverytoday.com/view/16329/metabolomics-study-provides-insight-into-gliomaassociated-metabolic-changes/ http://www.drugdiscoverytoday.com/view/16270/mental-health-problems-after-miscarriage-continue-after-healthy-birth/ Women who experience depression and anxiety after a miscarriage continue to experience these symptoms even if they subsequently go on to have a healthy child. Thu, 03 Mar 2011 00:01:00 GMT http://www.drugdiscoverytoday.com/view/16270/mental-health-problems-after-miscarriage-continue-after-healthy-birth/ http://www.drugdiscoverytoday.com/view/16254/waters-increases-the-number-of-its-speakers-at-its-upcoming-international-symposium-in-manchester/ The "6th International MS Symposium" is the latest in an occasional series of scientific meetings initiated (by Micromass) in 1998. Today these meetings are sponsored by Waters MS Technologies. The format is that of a legitimate scientific meeting, open to all, that typically attracts Ca 150+ delegates. Mon, 28 Feb 2011 15:28:00 GMT http://www.drugdiscoverytoday.com/view/16254/waters-increases-the-number-of-its-speakers-at-its-upcoming-international-symposium-in-manchester/ http://www.drugdiscoverytoday.com/view/16127/rnid-trih-to-accelerate-cures-for-hearing-loss-and-tinnitus-through-pioneering-new-initiative/ New medicines to prevent and treat hearing loss or tinnitus could be available within 10 years, if a bold new initiative by RNID succeeds in bringing scientists, pharmaceutical companies, funding bodies and private investors together to accelerate clinical trials. Wed, 23 Feb 2011 09:15:00 GMT http://www.drugdiscoverytoday.com/view/16127/rnid-trih-to-accelerate-cures-for-hearing-loss-and-tinnitus-through-pioneering-new-initiative/ http://www.drugdiscoverytoday.com/view/16106/rodent-models-meeting--need-for-reduced-drug-attrition-rates/ What are the strategies for reducing drug attrition rates in the clinic through the application of transgenic rodent models? Tue, 22 Feb 2011 11:23:00 GMT http://www.drugdiscoverytoday.com/view/16106/rodent-models-meeting--need-for-reduced-drug-attrition-rates/ http://www.drugdiscoverytoday.com/view/16090/budding-bioentrepreneurs-sought-for-biocity-boot-camp/ Applications are now being sought for the BioCity Boot Camp which will take place at BioCity Nottingham from 6th to 8th April 2011. Suited to recent graduates, post-docs and academic researchers - or simply those with experience within a larger organisation who feel the urge to break out on their own - the Boot Camp, formerly known as the Bio-Entrepreneur School, is ideal for anyone looking to commercialise a life science discovery, invention or great idea. Mon, 21 Feb 2011 12:58:00 GMT http://www.drugdiscoverytoday.com/view/16090/budding-bioentrepreneurs-sought-for-biocity-boot-camp/ http://www.drugdiscoverytoday.com/view/15911/advances-in-cell-based-screening-technologies-2011/ ELRIG (European Laboratory Robotics Interest Group) are hosting a free conference on the 15th March 2011 at Hinxton Hall, Cambridge UK on the topic of “Advances in Cell-Based Screening Technologies.With technological developments advancing at a seemly ever-increasing pace, methods of monitoring biological activity that a decade ago wouldn’t look out of place on Star Trek are beginning to filter into the lab.How are these being used, what can they tell us and what are the limitations? At this conference you will hear talks on the latest cutting edge detection technologies and biological techniques transitioning into screening labs. How are they faring and what might you using 10 years from now? Mon, 14 Feb 2011 15:19:00 GMT http://www.drugdiscoverytoday.com/view/15911/advances-in-cell-based-screening-technologies-2011/ http://www.drugdiscoverytoday.com/view/15568/biowales-march-1-and-2-showcases-countrys-biosciences-sector/ BioWales 2011 returns to the Vale Hotel near Cardiff on March 1st and 2nd with a conference, exhibition and biopartnering event reflecting the significance of the life sciences sector in Wales. Bringing together industry professionals, academics and clinicians, BioWales sets a platform to promote breakthroughs in new technologies, gain insights into the latest trends and developments and make valuable connections. Tue, 01 Feb 2011 09:16:00 GMT http://www.drugdiscoverytoday.com/view/15568/biowales-march-1-and-2-showcases-countrys-biosciences-sector/ http://www.drugdiscoverytoday.com/view/15555/astrazeneca-and-pfizer-join-cancer-research-uks-stratified-medicine-programme/ CANCER RESEARCH UK will be supported by AstraZeneca and Pfizer in a multimillion pound initiative to examine how genetic tests to improve cancer diagnosis can be best rolled out across the NHS.Cancer Research UK’s pioneering “Stratified Medicine Programme”* will also promote research into new targeted treatments by building a database of genetic information about tumours, treatments and survival rates that will enable researchers to design more effective cancer treatments in future. Tue, 01 Feb 2011 00:01:00 GMT http://www.drugdiscoverytoday.com/view/15555/astrazeneca-and-pfizer-join-cancer-research-uks-stratified-medicine-programme/ http://www.drugdiscoverytoday.com/view/15539/plankton-inspires-creation-of-stealth-armour-for-slow-release-microscopic-drug-vehicles/ The ability of some forms of plankton and bacteria to build an extra natural layer of nanoparticle-like armour has inspired chemists at the University of Warwick to devise a startlingly simple way to give drug bearing polymer vesicles (microscopic polymer based sacs of liquid) their own armoured protection. The Warwick researchers have been able to decorate these hollow structures with a variety of nanoparticles opening a new strategy in the design of vehicles for drug release, for example by giving the vesicle “stealth” capabilities which can avoid the body’s defences while releasing the drug. Mon, 31 Jan 2011 09:17:00 GMT http://www.drugdiscoverytoday.com/view/15539/plankton-inspires-creation-of-stealth-armour-for-slow-release-microscopic-drug-vehicles/ http://www.drugdiscoverytoday.com/view/15525/mechanistic-pharmacology-new-developments/ In this Editors Choice newsletter, I wanted to highlight some of the recent excellent content that is being published in our sister journal, Drug Discovery Today: Technologies. In particular, I wanted to bring to your attention some excellent papers from our Spring 2010 issue, entitled: Mechanistic Pharmacology, New Developments. Fri, 28 Jan 2011 14:45:00 GMT http://www.drugdiscoverytoday.com/view/15525/mechanistic-pharmacology-new-developments/ http://www.drugdiscoverytoday.com/view/15287/gsk-and-prosensa-announce-start-of-phase-iii-study-of-investigational-duchenne-muscular-dystrophy-medication/ GlaxoSmithKline (GSK) and Prosensa today announced that the first patient has commenced treatment in the Phase III study investigating GSK2402968, in ambulant boys with Duchenne Muscular Dystrophy (DMD), who have a dystrophin gene mutation amenable to an exon 51 skip Wed, 19 Jan 2011 14:22:00 GMT http://www.drugdiscoverytoday.com/view/15287/gsk-and-prosensa-announce-start-of-phase-iii-study-of-investigational-duchenne-muscular-dystrophy-medication/